Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urodilatin and Mannitol for Nephrotoxicity Prevention in BMT
NCT00390624Phase 2Completed
- Sponsor
- Rocky Mountain Cancer Centers
- Start
- Jul 2003
- Primary completion
- Dec 2006
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ularitide in nephrotoxicity, acute kidney injury (AKI), sponsored by Rocky Mountain Cancer Centers. Started Jul 2003; status: completed.
02
Drugs
ularitide
03
Conditions
nephrotoxicityacute kidney injury (AKI)
Beyond the preview
Go deeper on NCT00390624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390624.